Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)

Crinetics Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $93.0 million for Q2 2018.

• In Q2 2018, Preferred Stock Liabilities changed N/A year-over-year to $93.0 million; the TTM figure through Jun 2018 stood at $93.0 million (changed N/A YoY), while the FY2017 annual figure was $29.7 million, up 67.42% from the prior year.
• Preferred Stock Liabilities for Q2 2018 stood at $93.0 million, up from $29.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $93.0 million in Q2 2018, with the low at $29.7 million in Q4 2017.